#USA #Tampa #Concept Medical #Sirolimus Balloon #TRANSFORM II

Sirolimus-Coated Balloon Matches Drug-Eluting Stent Outcomes in TRANSFORM II Trial

Recent advancements in cardiovascular treatments have emerged from the TRANSFORM II trial, which evaluated the efficacy of a Sirolimus-coated balloon (SCB) compared to contemporary everolimus-eluting stents (EES). Presented as a groundbreaking late-breaking clinical trial at TCT 2026 and soon to be published in The Lancet, the findings hold significant implications for treating de novo coronary artery disease.

The study enrolled 1,842 patients across 53 centers in 11 countries in Europe, Asia, and South America, focusing on those with native coronary lesions. Patients were randomized to receive either the MagicTouch SCB, developed by Concept Medical, or the EES implantation, with the crucial lesion preparation completed before randomization, as endorsed by the Drug-Coated Balloon Academic Research Consortium. This specific approach aimed to observe whether an implant-free strategy could yield comparable results to standard stent practices.

The results revealed a remarkable similarity in outcomes between the two groups after 12 months. Target Lesion Failure (TLF), which encompasses cardiac death, myocardial infarction, and ischemia-driven revascularization, occurred in 2.1% of patients receiving the SCB treatment and 2.4% in those receiving EES, achieving a hazard ratio of 0.86. This data not only passes the non-inferiority margin but also underscores the potential of SCB therapy as a viable alternative to stenting procedures.

A key finding in the trial was the minimal need for bailout stenting — required in only 7.6% of those in the SCB group compared to prior studies where the need was more prevalent. More compelling is the absence of definite or probable lesion thrombosis in the SCB group, contrasting with a 0.2% rate in the EES candidates. In terms of net adverse clinical events, which include bleeding rates, the SCB exhibited numerically lower occurrences at 4.1%, against the 5.3% noted in the EES category.

These findings suggest that when combined with thorough lesion preparation, a sirolimus-coated balloon can yield similar clinical outcomes to drug-eluting stents — potentially redirecting the practice of percutaneous coronary intervention (PCI) towards strategies that prioritize non-invasive solutions. Dr. Bernardo Cortese, Principal Investigator, emphasizes that this study illustrates that treating well-prepared lesions with SCB can match or exceed traditional methods, highlighting the importance of adopting drug-coated balloon angioplasty as a foundational strategy rather than a mere substitute for stents.

Despite the promising results, the investigators acknowledge that further studies are necessary to explore the long-term effects of avoiding permanent implants, particularly concerning very late device-related events. Thus, the follow-up phase of the trial will continue for five years. The event rates encountered were lower than expected, yet it is essential to clarify that these outcomes pertain to lesions amenable to successful preparation, excluding severely calcified or complex lesions.

The TRANSFORM II trial was sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS in Milan, Italy, backed by an unrestricted research grant from Concept Medical. It's imperative to note that Concept Medical had no involvement in the trial’s design, analysis, or reporting process. Such studies reinforce the pivotal changes shaping modern PCI practices, gradually leading to a paradigm shift in how cardiovascular diseases are addressed globally. As research progresses, the opportunity to refine treatment approaches, reduce permanent device placements, and improve patient outcomes remains at the forefront of cardiovascular innovation.

For further updates on this trial and advancements in cardiovascular treatment, visit the websites of the involved institutions or follow ongoing discussions in medical journals and conferences.